Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
Abstract Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extr...
Saved in:
Main Authors: | Xinwen Wang, Min Wang, Qijun Lin, Lixin He, Baolin Zhang, Xin Chen, Guanhong Chen, Hong Du, Chuandong Lang, Xinsheng Peng, Yuhu Dai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202407662 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
by: Agathe Bessot, et al.
Published: (2025-02-01) -
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01) -
Efficacy of the Bushen Jianpi Huoxue Formula on Beclin-1/Bcl-2-mediated autophagy and apoptosis in osteoblasts
by: Yanping Lin, et al.
Published: (2025-01-01) -
SOCS domain targets ECM assembly in lung fibroblasts and experimental lung fibrosis
by: Carina Magdaleno, et al.
Published: (2024-12-01) -
Research of ECMS Energy Management Strategy of Hybrid System based on Grey Forecasting
by: Deng Tao, et al.
Published: (2017-01-01)